BioBots is an American biotechnology startup with a focus on computer science and chemistry. The company's first product is a 3D printer that prints biomaterials and was recently unveiled at the TechCrunch Disrupt conference in New York. According to co-founder Danny Cabrera, the printer combines hardware, software and wetware (the brain's nervous system, corresponding to computer hardware and software), and the wet parts part of them reflect their Core innovation technology. Biomanufacturing is the process of artificially making a living biological tissue structure. This is not an emerging field, and people have been studying it for decades. But Cabrera and his co-founders are convinced that they have discovered a new business opportunity to replace the traditionally expensive (over $100,000), bulky and complex equipment with new equipment. According to reports, they are inspired by small and low-cost desktop 3D printers. Ordinary 3D printers use plastic for printing, while BioBots' 3D printers use special inks. This ink consists of biological materials and living cells that can be used to print 3D living biological tissues and miniature human organs. Currently, the products they print can be used for screening before scientific research and clinical stages, such as replacing animals for drug testing. Although the field of biomanufacturing is gradually moving toward the manufacture of alternative human organs, BioBots is still unable to use human cells to print out replaceable organs. According to Cabrera, in the short term, the potential use of the company's technology will be to help develop specific disease treatments. He said: "We really just regard this device as a pharmaceutical company's product, only for clinical drug testing. You can use the human cell to print out the living biological tissue model with the help of our equipment, and these models are more than Traditional 2D organizations are more complex and sophisticated. These printed tissue models summarize the functions of the human body, and you can use them to develop compounds for clinical practice, so that you can find false positives before entering the clinical trial phase. Case." “We think this technology is a way to develop a personalized treatment plan. After the patient comes to the clinic, doctors can directly extract their cells and print 3D tissue, micro-tissue, and then use these personalized products to test different treatments for patients. Program, drug efficacy. Similarly, doctors can also develop personalized treatments for patients with specific conditions." “In the traditional method, we grouped some diseases into one category and gave them a name. But these diseases are different in each person's performance. And the drug development process is not keeping up with the times – we are always In an expensive clinical trial, we developed a drug that can be applied to thousands of patients, but we can't develop personalized drugs. But today, technology makes personalized drugs a reality, we can develop a drug for a patient alone. He added. BioBots was originally an entrepreneurial project that originated in a university residence. In July last year, when the two co-founders received degrees in computer science and biology from the University of Pennsylvania, they became interested in genetic engineering and tissue engineering. Cabrera said: "Our idea is that we can use the same way as traditional 3D printers to create a smaller, cheaper biotech device. At the time, the equipment in the traditional bio-manufacturing sector was huge. It looks like an old computer host that can occupy the entire room. And those devices usually cost $500,000 and are very difficult to operate. You need to find a professional technician to get the job done." BioBots won $5,000 in the early days of the University of Pennsylvania and developed their first prototype. Since then, they have successfully sold a device to a Ph.D. student and passed the screening of the Dreamit Health Accelerator Program in Pennsylvania. They joined the project last fall and received $50,000 in funding. Currently, the company's first generation of biomaterial printing equipment has been shipped. They work closely with researchers to continually debug their first generation products. It is reported that if researchers are willing to help BioBots in research and development, they will buy this 3D printing device for $5,000. Their business model is to sell different types of ink to researchers, and different inks can print different biomaterials. They launched a beta version of the Cartilage Tissue Ink Kit for $700. BioBots' printers use blue visible light and a complex photoinitiator with specific inks to process biological tissue, rather than using UV and pressure to finish printing like other devices. Cabrera said that their method is more efficient, because the use of pressure and ultraviolet light to print living tissue can damage living cells, while blue visible light does not adversely affect cells. To use this device to create biological tissue (such as a piece of bone, cartilage, or liver), users need to assemble the company's photoinitiator powder with the living cells they want to print. At the same time, they also need to add binding factors to ensure that the cells bind together. Cabrera explained: "Our ink consists of three powders. Users need to add the binding factor and the living cells they want to use. Wait for 5-10 minutes after mixing, then add these substances to the printing device. We need to use CAD design software such as AutoCAD and Solidworks to complete the structural design work. Our software can convert the design files into instructions that the printer can recognize." BioBots' 3D printers have an internal press that uses hydraulic pressure to squeeze the material out of the nozzle. Once the biomaterial is printed, the device uses blue visible light to complete the structural hardening. The time of printing varies depending on the content of the print, depending on the type of tissue you are trying to make. “So far, our customers have printed bones, lungs, liver, heart, brain, skin and cartilage,†Cabrera said. 1% salidroside in rhodiola rose extract is a kind of rhodiola rose extract, is the Key Product of our company, with the stem and leaves of rhodiola rhodiola as raw materials, after extraction, concentration, drying into brown powder. Rhodiola Rosea,Rhodiola Rosea Powder,Rhodiola Rosea Extract Benefits,Rhodiola Rosea Extract Holland Shaanxi Kepler Biotech Co.,Ltd , https://www.keplerherb.com
Rhodiola rhodiola extract is a natural extract extracted from Rhodiola grandiflora, which is refined, concentrated and dried.It is easily soluble in water, soluble in methanol, soluble in ethanol, insoluble in ether.It's stable against heat.
Rhodiola, the name of traditional Chinese medicine.They are the dry roots and rhizomes of Rhodiola roseum, .Mainly produced in the Chinese mainland Jilin, Hebei, Shanxi, Xinjiang and other places."Traditional Chinese Medicine Dictionary" records: Rhodiola "cold, sweet and astringent taste.Promote blood and stop bleeding, clear lung and stop cough.Treatment of cough, hemoptysis, pneumonia cough.
Rhodiola rhodiola is commonly found wild on sunny slopes, stone crevices, alpine meadows, alpine rock crevices, hillside grasslands, shrub margins, and dry sandy soils in mountains.Its adaptability is strong, like slightly cold and humid climate conditions, cold and drought tolerance, soil requirements are not very strict, should choose high altitude, cold climate, short frost-free period, summer day and night big temperature difference in the mountain cultivation.
Loam or sandy loam with rich humus, deep soil layer, sufficient sunshine and good drainage should be selected for cultivation, and forest cut or raw wasteland can be used for cultivation in mountainous areas.